Biotech
Commented by Fabian Lorenz on August 9th, 2023 | 07:00 CEST
After BioNTech shock: Evotec, Morphosys and Cardiol Therapeutics emerge as the new biotech favorites
BioNTech startled investors and analysts with its quarterly figures on Monday. Yet the biotech segment has actually developed positively in recent months. Several stocks are currently going full throttle, and S&P's sector index also outperformed the S&P 500 and MSCI World in July. This could finally signal the end of the underperformance of recent years, and biotech stocks could be celebrating a comeback. On the German stock charts, Evotec and Morphosys are among the high flyers. Both shares have performed strongly since April. Cardiol Therapeutics also looks promising from a technical chart perspective, and analysts see a price potential of over 200%. In contrast, there is currently no reason to buy BioNTech. Instead, investors should also bet on strength.
Read
Commented by André Will-Laudien on August 7th, 2023 | 07:55 CEST
Wild times - quarterly figures on the move! Tupperware, Defence Therapeutics, PayPal and Amazon under the magnifying glass!
After a pronounced summer rally on the stock markets, there have been individual setbacks in early August. It should come as no surprise that the reaction to quarterly figures can sometimes be more intense. Often, stocks have simply run too far and experienced a healthy consolidation; in the case of Tupperware, the opposite is probably the case. Here, too many speculators have positioned themselves on the short side, and there were hopeful reports. We analyze a few highlights of the last week.
Read
Commented by Stefan Feulner on August 2nd, 2023 | 09:15 CEST
Well positioned for the future - BioNTech, Defence Therapeutics, Sanofi
There is currently a lot of movement in the capital-intensive biotech sector. After second-tier companies, in particular, were hit hard by the effects of tighter monetary policy last year and at times traded below their cash levels, many are now considered hot takeover candidates thanks to their innovative technologies. The well-heeled pharma giants must act to avoid missing out on future blockbusters.
Read
Commented by Stefan Feulner on August 1st, 2023 | 09:00 CEST
Biogen, Cardiol Therapeutics, Evotec - The acquisition wave is rolling
The biotechnology industry has seen a significant increase in acquisitions and mergers in recent months. Large pharmaceutical companies are looking to expand their portfolios to provide innovative solutions for unmet medical needs. At the same time, despite an increase in value in recent months, acquisition targets are still attractively valued due to the sell-off over the past year.
Read
Commented by Armin Schulz on July 27th, 2023 | 07:15 CEST
BioNTech, Defiance Silver, Vonovia - Waiting for the turnaround
The stock market is not a one-way street, so it happens time and again that companies that initially performed well run into problems, leading to falling prices. After an extended period of underperformance, bargain hunters often step in, seeking the right entry point to profit from a potential turnaround. One announcement can turn the tide and influence the price of a stock. We have selected three candidates where a turnaround could be imminent, provided an appropriate news catalyst exists.
Read
Commented by Stefan Feulner on July 25th, 2023 | 09:45 CEST
Sartorius, BioNxt Solutions, CENIT AG - Attack from the Second Row
While some of the big caps have already reached new highs in the current stock market year 2023, many undiscovered second-tier stocks are still a long way off. At the same time, companies, most of which rely on disruptive technologies, possess powerful potential. If the ambitious goals are achieved, investors can expect above-average returns.
Read
Commented by Armin Schulz on July 19th, 2023 | 07:45 CEST
Pfizer, Cardiol Therapeutics, Bayer - Pharma facing turnaround despite drug shortages?
In mid-June, there was a shortage of 470 prescription drugs in Germany, according to the Federal Institute for Drugs and Medical Devices. However, not only Germany is suffering from a shortage, but all of Europe. Once again, the dependence on China is the underlying cause. The EU is seeking countermeasures, but this will be challenging because capped prices, bureaucracy and rising energy costs make a location like Germany seem less attractive. At the same time, demographic change means that society needs the pharmaceutical industry more and more urgently. Therefore, we look at three companies that aim to heal sick people.
Read
Commented by Nico Popp on July 11th, 2023 | 07:30 CEST
Returns thanks to e-prescription and co.: Redcare Pharmacy, BB Biotech, Cardiol Therapeutics
There are attractive returns to be had in the healthcare sector. Innovative approaches around data and biotechnology are particularly promising, according to Daniel Matviyenko, Portfolio Manager of Healthcare Strategies at Jennison Associates. But what does this innovation look like in concrete terms? And how can investors invest? We highlight the healthcare industry using three companies as examples, with a special focus on opportunities in select individual stocks.
Read
Commented by Armin Schulz on July 6th, 2023 | 07:55 CEST
TUI, Defence Therapeutics, Plug Power - Who has the potential for a rally?
The search for stocks with the potential for a rally is an exciting and promising task for investors. There are several approaches and strategies to find appropriate stocks. One commonly used approach is fundamental analysis, which examines a company's financial health, business models, growth prospects and other fundamental factors. Solid fundamental analysis can help identify companies with strong potential for future growth. We have chosen three companies with strong upside potential.
Read
Commented by André Will-Laudien on July 5th, 2023 | 07:55 CEST
666% rally in 5 years - can Nucera do even more? BioNTech, BioNxt Solutions, and Plug Power could be the winners!
The story of the Mainz-based biotech company BioNTech has set a precedent over the last 5 years. With a remaining gain of 666%, it still ranks among the best performers on the German stock market, even after a 75% price decline. Such movements usually take place on the NASDAQ, where it is easy for highly innovative technology or biotech stocks to raise the necessary growth capital. But not every stock market story is so positive. We go on a pearl diver's journey.
Read